ProQR Therapeutics presenting keynote at Oligonucleotide
SMi reports: SMi are pleased to inform you that Vera Brinks, Director Pharmaceutics from ProQR Therapeutics has confirmed her position as speaker
SMi are pleased to inform you that Vera Brinks, Director Pharmaceutics from ProQR Therapeutics has confirmed her position as speaker at the upcoming Oligonucleotide Therapeutics and Delivery conference in September.
Vera will be presenting:
Oligonucleotide DP development and manufacturing for orphan ophthalmic diseases
- An overview of oligonucleotide products in development at ProQR Therapeutics for (ultra) orphan ophthalmic diseases
- Outlining the DP development challenges related to intravitreal (IVT) administered products
- Assessment and implementation of terminal sterilization of oligonucleotide products in development at ProQR Therapeutics
Vera Brinks is director pharmaceutics at ProQR Therapeutics, Leiden, the Netherlands. With her team she is responsible for early and late phase oligonucleotide DP development. Vera received her PhD in 2009 in the field of biopharmaceutics at the Leiden University (The Netherlands). Before joining ProQR 6 years ago, Vera has worked as postdoctoral fellow at the FDA (CDER, DTP), and as postdoctoral researcher at the Utrecht University (the Netherlands) for 6 years. She has over 25 publications in the field of therapeutic proteins, biosimilars and formulation-related quality attributes.
The event brochure with the full agenda and speaker line-up is available to download: www.oligonucleotide.co.uk/pharmapr5
Oligonucleotide Therapeutics and Delivery
Main conference: 16th – 17th September 2020
Proudly sponsored by: ChemGenes & Tosho Bioscience
For media queries please contact Jinna Sidhu at email@example.com or call +44 (0)20 7827 6088
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk